JP2005528337A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528337A5
JP2005528337A5 JP2003558463A JP2003558463A JP2005528337A5 JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5 JP 2003558463 A JP2003558463 A JP 2003558463A JP 2003558463 A JP2003558463 A JP 2003558463A JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5
Authority
JP
Japan
Prior art keywords
xaa
gly
ser
glp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003558463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528337A (ja
JP4282485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/000001 external-priority patent/WO2003058203A2/en
Publication of JP2005528337A publication Critical patent/JP2005528337A/ja
Publication of JP2005528337A5 publication Critical patent/JP2005528337A5/ja
Application granted granted Critical
Publication of JP4282485B2 publication Critical patent/JP4282485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003558463A 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ Expired - Fee Related JP4282485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34647402P 2002-01-08 2002-01-08
US40509702P 2002-08-21 2002-08-21
PCT/US2003/000001 WO2003058203A2 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Publications (3)

Publication Number Publication Date
JP2005528337A JP2005528337A (ja) 2005-09-22
JP2005528337A5 true JP2005528337A5 (enExample) 2006-02-02
JP4282485B2 JP4282485B2 (ja) 2009-06-24

Family

ID=26994870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558463A Expired - Fee Related JP4282485B2 (ja) 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ

Country Status (11)

Country Link
US (1) US7482321B2 (enExample)
EP (1) EP1585959A4 (enExample)
JP (1) JP4282485B2 (enExample)
AR (1) AR038102A1 (enExample)
AU (1) AU2003200839B2 (enExample)
BR (1) BR0306706A (enExample)
CA (1) CA2468700A1 (enExample)
MX (1) MXPA04006679A (enExample)
PE (1) PE20030820A1 (enExample)
TW (1) TW200306202A (enExample)
WO (1) WO2003058203A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1709071A4 (en) 2004-01-08 2007-05-30 Theratechnologies Inc GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2006023367A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US8097586B2 (en) 2005-01-14 2012-01-17 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exedins and uses thereof
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007017892A2 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
SI1881850T1 (sl) * 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
WO2007021498A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
RS51319B (sr) * 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
KR101057284B1 (ko) 2005-10-26 2011-08-16 일라이 릴리 앤드 캄파니 선택적 vpac2 수용체 펩티드 작동제
PL1965823T3 (pl) * 2005-11-04 2017-08-31 Glaxosmithkline Llc Sposoby podawania środków hipoglikemicznych
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
JP2009528376A (ja) * 2006-02-28 2009-08-06 イーライ リリー アンド カンパニー 選択的vpac2受容体ペプチドアゴニスト
WO2007113205A1 (en) * 2006-04-03 2007-10-11 Novo Nordisk A/S Glp-1 peptide agonists
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
TWI541023B (zh) * 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
CN105748402B (zh) 2010-11-24 2022-06-03 杜雷科特公司 生物可降解的药物递送组合物
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプターコアゴニスト
EP2729157B1 (en) * 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
TW201334791A (zh) 2011-11-23 2013-09-01 杜瑞克公司 輻射滅菌之可生物降解之藥物遞送組合物
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
AU2014283221A1 (en) * 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
EP1060191B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN

Similar Documents

Publication Publication Date Title
US10961287B2 (en) Extended recombinant polypeptides and compositions comprising same
JP2008533105A5 (enExample)
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
JP2014529629A5 (enExample)
CN101993485B (zh) 促胰岛素分泌肽类似物同源二聚体及其用途
RU2006120079A (ru) Производные глюкагоноподобного пептида-1 (glp-1)
JP2003505347A5 (enExample)
JP2001011095A5 (enExample)
RU2007119990A (ru) Слитые конструкции лекарственного средства и конъюгаты
JP4227894B2 (ja) グルカゴン様ペプチド1アナログ
EP2729481B1 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2013517307A5 (enExample)
JP2013543853A5 (enExample)
PE20231842A1 (es) Coagonistas de los receptores de glp-1 y gip
TW201010729A (en) GIP-based mixed agonists for treatment of metabolic disorders and obesity
JP2002538081A (ja) Glp−1の類似体
JP2005528337A (ja) 伸長グルカゴン様ペプチド−1アナログ
JP2007519642A5 (enExample)
TW200848423A (en) Glucagon/GLP-1 receptor co-agonists
JP2014501712A5 (enExample)
AU2003200839A2 (en) Extended glucagon-like peptide-1 analogs
JP2012529297A5 (enExample)
JP2005519059A5 (enExample)
RU2005115477A (ru) Нейтрализующие антитела против gdf-8 и их применение
JP2004501162A5 (enExample)